Tracers / [177Lu]Lu-NeoB
[177Lu]Lu-NeoB
Also written as [Lu-177]Lu-NeoB; [Lu-177]NeoB
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- phase I/IIa clinical trial (first-in-human)
- Syntheses indexed
- 2
What it is
- Compound class
- GRPR-targeting peptide (bombesin analog)
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPR) antagonist/binder PMID 41344852
- Clinical application
- Radioligand therapy for advanced solid tumors overexpressing GRPR (e.g., gastrointestinal stromal tumors, prostate cancer, glioblastoma, breast cancer) in phase 1 first-in-human study PMID 41344852
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 41344852 2026 J Nucl Med |
| Manual synthesis | — | — | >98% | >97% | NeoB | 37584725 2023 Eur J Nucl Med Mol Imaging NeoB and RM2 were synthesized as described in Supplementary material 1. — [177Lu]Lu-NeoB and [177Lu]Lu-RM2 were obtained in > 98% RCY and > 97% RCP. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-NeoB, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 41344852: 'NeoRay is a prospective, phase 1/2a, open-label, multicenter, first-in-human study of 177Lu-NeoB.'.